SG10201913641XA - Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis Kits - Google Patents
Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis KitsInfo
- Publication number
- SG10201913641XA SG10201913641XA SG10201913641XA SG10201913641XA SG10201913641XA SG 10201913641X A SG10201913641X A SG 10201913641XA SG 10201913641X A SG10201913641X A SG 10201913641XA SG 10201913641X A SG10201913641X A SG 10201913641XA SG 10201913641X A SG10201913641X A SG 10201913641XA
- Authority
- SG
- Singapore
- Prior art keywords
- prophylaxis
- kits
- treatment methods
- viral
- exposure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021589P | 2014-07-07 | 2014-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913641XA true SG10201913641XA (en) | 2020-03-30 |
Family
ID=55016233
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700061PA SG11201700061PA (en) | 2014-07-07 | 2015-07-07 | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| SG10201913641XA SG10201913641XA (en) | 2014-07-07 | 2015-07-07 | Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis Kits |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700061PA SG11201700061PA (en) | 2014-07-07 | 2015-07-07 | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10052329B2 (en) |
| EP (2) | EP4342545A2 (en) |
| JP (3) | JP2017527610A (en) |
| KR (1) | KR20170063512A (en) |
| CN (2) | CN114469958A (en) |
| AU (3) | AU2015287994B2 (en) |
| BR (1) | BR112017000285A2 (en) |
| CA (1) | CA2954526C (en) |
| ES (1) | ES2964529T3 (en) |
| IL (2) | IL249938B (en) |
| MX (1) | MX2017000059A (en) |
| PL (1) | PL3166680T3 (en) |
| SG (2) | SG11201700061PA (en) |
| WO (1) | WO2016007538A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11071745B2 (en) | 2014-07-07 | 2021-07-27 | Elian Llc | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| EP4342545A2 (en) | 2014-07-07 | 2024-03-27 | Elian LLC | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| KR102607599B1 (en) * | 2017-02-08 | 2023-11-28 | 바이오트론 리미티드 | How to treat influenza |
| CA3067906A1 (en) * | 2017-06-28 | 2019-01-03 | Aicuris Anti-Infective Cures Gmbh | Intravaginally applicable devices comprising antiviral compounds |
| WO2020086705A2 (en) * | 2018-10-23 | 2020-04-30 | Eastern Virginia Medical School | Pharmaceutical compositions and methods of making on demand solid dosage formulations |
| WO2020092990A1 (en) * | 2018-11-02 | 2020-05-07 | Eastern Virginia Medical School | Pharmaceutical compositions and methods of making a patch formulation for transdermal delivery |
| MX2021010063A (en) * | 2019-02-25 | 2021-11-12 | Elian Llc | Treatment of herpes simplex with a combination of valacyclovir and famciclovir. |
| US20210322469A1 (en) * | 2020-04-20 | 2021-10-21 | Regents Of The University Of Minnesota | Zinc and copper for the prophylaxis and treatment of covid-19 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795721A (en) | 1990-06-11 | 1998-08-18 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of ICP4 |
| ES2284250T3 (en) * | 1998-04-21 | 2007-11-01 | Infectio Recherche Inc. | FORMULATIONS FOR THE PREVENTION OR TREATMENT OF DISEASES AFFECTING MUCOUS MEMBRANE OR SKIN, OR FOR PREVENTION OF PREGNANCY. |
| GB9819898D0 (en) * | 1998-09-11 | 1998-11-04 | Smithkline Beecham Plc | New vaccine and method of use |
| DOP2000000109A (en) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | THIAZOLILAMIDE DERIVATIVES |
| US20020091097A1 (en) | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
| EP1996209B1 (en) * | 2006-03-22 | 2015-11-04 | Starpharma Pty Limited | Contraceptive composition |
| WO2009142827A2 (en) | 2008-03-28 | 2009-11-26 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and methods for the treatment of viral infection |
| US8853223B2 (en) * | 2010-09-17 | 2014-10-07 | G2L Touch, Inc. | Therapeutic composition to treat lesions caused by herpes simplex virus |
| ES2551738T3 (en) * | 2010-06-11 | 2015-11-23 | Gilead Sciences, Inc. | Topical antiviral formulations for the prevention of HSV-2 transmission |
| WO2012158779A1 (en) * | 2011-05-17 | 2012-11-22 | Reprotect, Inc. | Reusable intravaginal delivery device, system, and method |
| EP2734262B1 (en) * | 2011-07-20 | 2018-02-28 | Patrick F. Kiser | Intravaginal rings for drug delivery |
| PL2850431T3 (en) * | 2012-05-16 | 2018-09-28 | Immune Design Corp. | Vaccines for hsv-2 |
| EP4342545A2 (en) | 2014-07-07 | 2024-03-27 | Elian LLC | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
-
2015
- 2015-07-07 EP EP23209083.7A patent/EP4342545A2/en active Pending
- 2015-07-07 WO PCT/US2015/039421 patent/WO2016007538A1/en active Application Filing
- 2015-07-07 EP EP15818554.6A patent/EP3166680B1/en active Active
- 2015-07-07 US US14/793,550 patent/US10052329B2/en active Active
- 2015-07-07 BR BR112017000285A patent/BR112017000285A2/en not_active Application Discontinuation
- 2015-07-07 AU AU2015287994A patent/AU2015287994B2/en active Active
- 2015-07-07 MX MX2017000059A patent/MX2017000059A/en unknown
- 2015-07-07 SG SG11201700061PA patent/SG11201700061PA/en unknown
- 2015-07-07 CA CA2954526A patent/CA2954526C/en active Active
- 2015-07-07 JP JP2017522446A patent/JP2017527610A/en active Pending
- 2015-07-07 PL PL15818554.6T patent/PL3166680T3/en unknown
- 2015-07-07 CN CN202111625589.0A patent/CN114469958A/en active Pending
- 2015-07-07 CN CN201580048049.7A patent/CN106794336B/en active Active
- 2015-07-07 KR KR1020177003101A patent/KR20170063512A/en not_active IP Right Cessation
- 2015-07-07 ES ES15818554T patent/ES2964529T3/en active Active
- 2015-07-07 SG SG10201913641XA patent/SG10201913641XA/en unknown
-
2017
- 2017-01-05 IL IL249938A patent/IL249938B/en active IP Right Grant
-
2020
- 2020-04-12 IL IL273932A patent/IL273932B2/en unknown
- 2020-06-12 AU AU2020203896A patent/AU2020203896B2/en active Active
-
2021
- 2021-05-21 JP JP2021086021A patent/JP2021138723A/en active Pending
-
2022
- 2022-11-25 AU AU2022275517A patent/AU2022275517A1/en active Pending
-
2023
- 2023-09-27 JP JP2023166253A patent/JP2023179575A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020203896A1 (en) | 2020-07-02 |
| US10052329B2 (en) | 2018-08-21 |
| EP3166680A1 (en) | 2017-05-17 |
| AU2015287994B2 (en) | 2020-03-12 |
| US20160000797A1 (en) | 2016-01-07 |
| JP2017527610A (en) | 2017-09-21 |
| ES2964529T3 (en) | 2024-04-08 |
| BR112017000285A2 (en) | 2017-10-31 |
| EP3166680C0 (en) | 2023-11-15 |
| EP3166680B1 (en) | 2023-11-15 |
| AU2020203896B2 (en) | 2022-08-25 |
| CA2954526A1 (en) | 2016-01-14 |
| IL249938A0 (en) | 2017-03-30 |
| IL273932B2 (en) | 2023-07-01 |
| JP2023179575A (en) | 2023-12-19 |
| JP2021138723A (en) | 2021-09-16 |
| IL249938B (en) | 2020-04-30 |
| CN106794336A (en) | 2017-05-31 |
| WO2016007538A1 (en) | 2016-01-14 |
| EP4342545A2 (en) | 2024-03-27 |
| SG11201700061PA (en) | 2017-02-27 |
| CN114469958A (en) | 2022-05-13 |
| AU2015287994A1 (en) | 2017-02-02 |
| MX2017000059A (en) | 2017-11-08 |
| PL3166680T3 (en) | 2024-03-25 |
| IL273932B1 (en) | 2023-03-01 |
| AU2022275517A1 (en) | 2023-01-05 |
| CA2954526C (en) | 2023-03-07 |
| KR20170063512A (en) | 2017-06-08 |
| CN106794336B (en) | 2022-01-11 |
| IL273932A (en) | 2020-05-31 |
| EP3166680A4 (en) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258795A1 (en) | Methods for treating filoviridae virus infections | |
| HK1243640A1 (en) | Methods and compositions for treating ulcers | |
| HK1252937A1 (en) | Methods and kits for treating depression | |
| GB201701673D0 (en) | Methods of well treatment | |
| IL248803A0 (en) | Means and methods for treating cmv | |
| IL251759A0 (en) | Compositions and methods for treating insomnia | |
| IL249938A0 (en) | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits | |
| EP3229906C0 (en) | Systems and methods for optimizing transskull acoustic treatment | |
| EP3133919A4 (en) | Agents and methods for treatment of pathogens | |
| IL251885A0 (en) | Noscapinoid-producing microbes and methods of making and using the same | |
| EP3174475C0 (en) | Catheter devices and kits | |
| GB201416832D0 (en) | Methods of treatment | |
| HK1249866A1 (en) | Methods of treatment with taselisib | |
| IL246643A0 (en) | Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome | |
| GB201402909D0 (en) | Treating infection | |
| GB201417372D0 (en) | Methods and kits | |
| HK1244782A1 (en) | Compositions and methods for treating diseases and conditions | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| EP3215180A4 (en) | Methods and kits for treating cardiovascular diseases | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201421904D0 (en) | Methods and kits | |
| GB201509908D0 (en) | Methods and kits | |
| AU2014902732A0 (en) | Treatment and prophylaxis | |
| AU2014901470A0 (en) | Agents and methods for treatment of pathogens |